Estimating the Danish Populations' Preferences for Pharmacogenetic Testing Using a Discrete Choice Experiment. The Case of Treating Depression

Herbild, Louise; Bech, Mickael; Gyrd‐Hansen, Dorte

doi:10.1111/j.1524-4733.2008.00465.x

Cited by 31 publications

(17 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, it is likely, that a shorter turnaround time may be preferred for a pharmacogenetic test that is used to inform prescribing in acute conditions, such as testing to inform warfarin prescribing to prevent thromboembolic disease [40]. Herbild et al [41] explored "willingness to pay" for a pharmacogenetic test using a four attribute web-based DCE to elicit preferences for the treatment of depression in terms of: changes in drug treatment, time with dosage adjustments due to adverse side effects and/or lack of effects, cost of pharmacogenetic testing, and the probability of benefits from pharmacogenetic testing. Findings suggest that if diagnosed with depression, peoples' willingness to pay for pharmacogenetic testing exceed price, as long as there is a 10% probability for improvements in treatment.…”

Section: Discussionmentioning

confidence: 99%

Valuing pharmacogenetic testing services: A comparison of patients' and health care professionals' preferences

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Valuing pharmacogenetic testing services: A comparison of patients' and health care professionals' preferences

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Regier et al evaluated the use of genomic testing to identify the genetic causes of developmental disability, reporting that both the diagnostic rate and waiting time for test results were important to families [41, 42]. Herbild et al evaluated WTP for pharmacogenetic testing in the treatment of depression and found that respondents placed a high value on how the intervention was delivered [43]. Finally, Najafzadeh et al measured the preferences of patients and the general public for genomic testing to determine drug response, finding that both clinical (e.g.…”

Section: Discussionmentioning

confidence: 99%

Patients’ Preferences for Genomic Diagnostic Testing in Chronic Lymphocytic Leukaemia: A Discrete Choice Experiment

Buchanan

Wordsworth

Schuh

2016

Patient

View full text Add to dashboard Cite

BackgroundGenomic information could help to reduce the morbidity effects of inappropriate treatment decisions in many disease areas, in particular cancer. However, evidence of the benefits that patients derive from genomic testing is limited. This study evaluated patient preferences for genomic testing in the context of chronic lymphocytic leukaemia (CLL).MethodsWe used a discrete choice experiment (DCE) survey to assess the preferences of CLL patients in the UK for genomic testing. The survey presented patients with 16 questions in which they had to choose between two possible test scenarios. Tests in these scenarios were specified in terms of six attributes, including test effectiveness, test reliability and time to receive results.Results219 patients completed the survey (response rate 20 %). Both clinical and process-related attributes were valued by respondents. Patients were willing to pay £24 for a 1 % increase in chemotherapy non-responders identified, and £27 to reduce time to receive test results by 1 day. Patients were also willing to wait an extra 29 days for test results if an additional one-third of chemotherapy non-responders could be identified, and would tolerate a genomic test being wrong 8 % of the time to receive this information.ConclusionCLL patients value the information that could be provided by genomic tests, and prefer combinations of test characteristics that more closely reflect future genomic testing practice than current genetic testing practice. Commissioners will need to carefully consider how genomic testing is operationalised in this context if the benefits of testing are to be realised.Electronic supplementary materialThe online version of this article (doi:10.1007/s40271-016-0172-1) contains supplementary material, which is available to authorized users.

show abstract

“…Earlier studies have shown that sample sizes of 300–400 respondents are sufficient for reliable statistical analyses [23], [24]. Therefore, first, we strived to collect at least 400 completed questionnaires.…”

Section: Methodsmentioning

confidence: 99%

Have Preferences of Girls Changed Almost 3 Years after the Much Debated Start of the HPV Vaccination Program in the Netherlands? A Discrete Choice Experiment

et al. 2014

View full text Add to dashboard Cite

ObjectivesTo assess how girls' preferences have changed almost 3 years after the much debated start of the human papillomavirus (HPV) vaccination program.MethodsA discrete choice experiment (DCE) was conducted among girls aged 11–15 years who were invited, or were not yet invited, to get vaccinated. A panel latent class model was used to determine girls' preferences for vaccination based on five characteristics: degree of protection against cervical cancer; duration of protection; risk of mild side-effects; age of vaccination; and the number of required doses of the vaccine.ResultsThe response rate was 85% (500/592). Most girls preferred vaccination at age 14 years (instead of at age 9 years) and a 2-dose scheme (instead of the current 3-dose scheme). Girls were willing to trade-off 7% (CI: 3.2% to 10.8%) of the degree of protection to have 10% less risk of mild side-effects, and 4% (CI: 1.2% to 5.9%) to receive 2 doses instead of 3 doses. Latent class analyses showed that there was preference heterogeneity among girls, i.e., higher educated girls and HPV vaccinated girls had a higher probability to opt for HPV vaccination at a higher age than lower educated girls or non-vaccinated girls.ConclusionsThree years after the start of HPV vaccination program the risk of mild side-effects and age at vaccination seem to have become less important. For the Dutch national immunization program, we recommend not to lower the current target age of 12 years. A 2-dose scheme may result in a higher uptake and we recommend that if this scheme is introduced, it needs to receive adequate publicity.

show abstract

Estimating the Danish Populations' Preferences for Pharmacogenetic Testing Using a Discrete Choice Experiment. The Case of Treating Depression

Cited by 31 publications

References 51 publications

Valuing pharmacogenetic testing services: A comparison of patients' and health care professionals' preferences

Valuing pharmacogenetic testing services: A comparison of patients' and health care professionals' preferences

Patients’ Preferences for Genomic Diagnostic Testing in Chronic Lymphocytic Leukaemia: A Discrete Choice Experiment

Have Preferences of Girls Changed Almost 3 Years after the Much Debated Start of the HPV Vaccination Program in the Netherlands? A Discrete Choice Experiment

Contact Info

Product

Resources

About